| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.2260 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.2676 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.2969 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.3024 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.3619 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.3735 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.3780 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.3834 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.4035 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.4141 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.4362 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.4474 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.4614 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.4792 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.4979 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.5481 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.5610 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.5729 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.5778 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.5856 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.5973 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.5974 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6041 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6046 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6056 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6205 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6349 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6421 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6526 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6637 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6649 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6659 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6674 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6694 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6708 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6762 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6803 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6847 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6885 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6907 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6947 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.6980 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7047 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7083 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7182 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7223 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7276 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7293 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7306 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7352 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7374 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7378 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7548 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7604 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7634 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7755 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.7759 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8070 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8096 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8181 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8315 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8354 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8426 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8449 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8537 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8587 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8652 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8753 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8765 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8818 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8875 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.8922 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9066 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9151 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9270 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9282 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9332 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9333 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9354 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9393 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9408 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9452 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9456 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9461 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9632 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9632 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9670 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9769 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9786 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9794 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9846 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9961 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 0.9975 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0000 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0039 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0060 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0223 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0319 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0458 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0551 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0563 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0565 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0591 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0770 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0880 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.0982 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1206 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1253 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1256 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1334 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1471 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1522 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1670 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1717 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1790 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.1805 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2040 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2203 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2219 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2331 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2387 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2457 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2662 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2694 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2741 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2781 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2884 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2895 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2935 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2973 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.2997 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.3137 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.3378 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.3496 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.3670 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.3979 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.4075 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.4148 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.4167 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.4464 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.4482 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.4631 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.5076 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.5173 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.5595 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.5842 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.5902 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.6034 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.6167 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.6405 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.6743 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.6875 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.6987 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.7006 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.7190 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.7753 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.7816 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.7870 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.8016 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.8490 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.8888 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.9289 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.9303 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.9450 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 1.9888 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.0889 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.1143 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.1287 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.2108 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.3282 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.3696 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.4809 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.5403 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.5747 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.5940 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.7371 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.7887 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.8530 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 2.8652 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 3.0012 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 3.0295 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 3.0319 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 3.1200 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 3.3256 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 3.5670 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 3.5978 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | margarate (17:0) | 4.3804 | scaled units | Placebo | +4HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|